Edwards Lifesciences has launched its new-gen transcatheter heart valve platform in India, marking a significant advance in the treatment of severe aortic stenosis. The system is intended for patients that are not suitable candidates for open-hear...
The Maharashtra Food and Drug Administration (FDA) has made substantial improvements to its testing facilities to address the continued high demand for drug regulation and quality testing. The FDA’s laboratories in Mumbai and Aurangabad have...
The plan by healthcare giant Manipal Hospitals to buy Pune-based Sahyadri Hospitals from international investor Ontario Teachers' Pension Plan Board in a deal valued at around Rs. 6,400 crore has been approved by the Competition Commission of India
At the ESC Congress 2025 that took place in Madrid, Novo Nordisk presented findings from the STEER study, which indicated that Wegovy (semaglutide 2.4 mg) provides greater protection to cardiovascular risk than tirzepatide for people living with...
Merck announced today positive topline data from its phase 3 CORALreef Lipids trial of enlicitide, an investigational oral PCSK9 inhibitor, in adults with hypercholesterolemia. The once-daily regimen achieved all primary and key secondary...
Novartis reported encouraging findings from V-DIFFERENCE, a phase IV study comparing Leqvio (inclisiran) to a placebo, both of which were given in addition to individually tailored lipid-lowering therapy (LLT), in patients with hypercholesterolemia
AstraZeneca plans to apply for regulatory approval for Blood Pressure Drug Baxdrostat before the end of this year, with approval expected in the U.S. and E.U. in 2026. The company views the opportunity in Baxdrostat as the crux of its strategy...
Mahajan Imaging & Labs, a pioneer in integrated diagnostics and advanced medical imaging, has entered a strategic alliance with Fortis La Femme, India’s leading hospital dedicated to women’s and children’s health, to create a new benchmark in...
Eli Lilly and Company announced positive top-line results in the Phase 3 ATTAIN-2 trial that evaluated, orforglipron, an investigational oral GLP-1 receptor agonist in adults with obesity or overweight and type 2 diabetes. The ATTAIN-2 trial showed
Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced the FDA approval and U.S. market availability of the first generic version of Saxenda
.jpg)
, CDSCO.jpg)